인간 마이크로바이옴 시장 규모, 점유율, 동향 및 예측 : 제품 유형별, 용도별, 질환별, 지역별(2026-2034년)

The global human microbiome market size was valued at USD 1,116.3 Million in 2025. Looking forward, IMARC Group estimates the market to reach USD 4,127.9 Million by 2034, exhibiting a CAGR of 15.17% from 2026-2034. North America currently dominates the market, holding a market share of 43.5% in 2025. At present, healthcare system is moving away from treatment-driven models to prevention-driven models. Moreover, ongoing developments in sequencing technologies and bioinformatics platforms is offering a favorable market outlook. Apart from this, the increasing knowledge regarding the connection between the health of the gut and general well-being is expanding the human microbiome market share.

The market for the human microbiome is growing fast as studies are revealing new uses in healthcare, nutrition, and biotechnology. The industry is seeing increasing investments from pharmaceuticals and biotechnology firms that are investigating microbiome therapeutic opportunities in chronic diseases, gastrointestinal diseases, and metabolic disorders. Firms are releasing innovative diagnostic products and tailored medicine solutions that are focusing on the functioning of the microbiome in overall health. The market is growing as the awareness about probiotics, prebiotics, and functional foods is rising among the consumer base. Fortified foods and dietary supplements are attracting increasing attention with manufacturers highlighting microbiome-friendly products. Concurrently, technological developments in sequencing and bioinformatics are making it possible to delve deeper into microbiome data, which is facilitating drug discovery and clinical development.

The United States human microbiome market is increasing consistently since research centers, biotech companies, and pharmaceutical industries are enhancing their interest in microbiome-based innovations. The market is experiencing increasing demand for microbiome-based therapies in the form of gastrointestinal disorders, autoimmune disorders, and metabolic diseases because the clinical relevance of the microbiome is being increasingly acknowledged. Firms are creating next-generation probiotics, prebiotics, and synbiotics, investing in personalized nutrition and precision medicine strategies that are targeting personal microbiome profiles. Government agencies and private investors are funding microbiome research to expand, accelerating clinical trials and product development. Sequencing tools and bioinformatics platforms are improving, enabling scientists to better analyze intricate microbial communities. These technological advancements are consolidating drug discovery pipelines and diagnostic solutions. Researchers at Stanford Medicine and their team monitored the bacteria found in the gut, mouth, nose, and skin of 86 individuals for up to six years in an effort to understand what defines a healthy microbiome. The study also identified various connections between the microbiome and health, for example, people with Type 2 diabetes exhibited a limited stability and less diverse microbiome

Human Microbiome Market Trends:

Greater Emphasis on Preventive Health and Personalized Medicine

The human microbiome industry is growing as the healthcare system is moving away from treatment-driven models to prevention-driven models. Consumers and patients are becoming more inclined towards the solutions that are enabling long-term well-being and decreasing the risk of non-communicable diseases. Personalized medicine is taking a pivotal position, as diagnostics and therapeutics based on the microbiome are being created to address unique microbiome profiles. Firms are integrating genetic sequencing and bioinformatics technologies to provide personalized interventions that are treating ailments like obesity, diabetes, autoimmune diseases, and gastrointestinal disorders. Not only is this revolutionizing consumer demand, but it is also drawing huge investments from pharmaceutical and biotech companies looking to develop precision therapies. With growing consciousness about the role of the microbiome in influencing immunity, metabolism, and mental well-being, adoption of personalized healthcare solutions is gaining momentum. The emphasis on personalized prevention strategies is thus supporting the human microbiome market growth. In 2025, Sova Health, the first comprehensive gut health company in India, is making a transformative move in digestive health. Renowned for its tailored probiotics and individualized gut-balancing solutions, the brand is now launching a series of diagnostic tools intended to enhance gut health accuracy and scientific support like never before. By introducing its Gut Microbiome Test (GMT) and Food Intolerance Test (FIT), the company stated that it intends to assist consumers in understanding their symptoms and customizing solutions to address them.

Advances in Sequencing and Bioinformatics

The market is growing fast with ongoing developments in sequencing technologies and bioinformatics platforms. Next-generation sequencing (NGS) is facilitating scientists to investigate microbial communities with high precision, speed, and efficiency. Bioinformatics solutions are becoming more sophisticated to analyze large data sets so that scientists can detect microbial biomarkers and study host-microbiome relationships more efficiently. These advances are enabling the discovery of new therapeutics, diagnostics, and foods through better understanding of the intricate workings of the human microbiome, thereby offering a favorbale human microbiome market outlook. The pharmaceutical and biotech industries are embracing these technologies to fast-track drug development and clinical trials, which is lowering development times enormously. Further, enhanced computational models are enabling predictive simulations that are assisting scientists in designing tailored interventions against selected diseases. As the cost of sequencing is reducing and computing powers are increasing, access to microbiome science is rising, thus providing further stimulation for innovation and industry growth. Technological advancements are hence an important driver supporting momentum. The publisher predicts that the global bioinformatics market is projected to attain USD 39.4 Billion by 2033.

Increasing Consumer Demand for Functional Foods and Supplements

One of the major human microbiome market trends includes the riding the wave of increasing knowledge regarding the connection between the health of the gut and general well-being. Consumers are taking up probiotics, prebiotics, and functional foods as part of their diet by the day due to worries over immunity, digestion, and prevention of chronic diseases. Food and beverage players are turning innovative by introducing microbiome-friendly products that are presented as natural, science-proven remedies for staying healthy. This is also being supported by the growing demand for personalized nutrition, where diet regimes and supplements are formulated based on an individual's microbiome profile. Social media, health campaigns, and science communication are disseminating information regarding the function of the microbiome, thus making changes to consumer behavior. Consumer retail channels and e-commerce platforms also increase accessibility to products that are microbiome-related, driving demand. Since health-aware consumers increasingly favor preventive care and natural remedies over drug therapy, the functional foods and supplements industry is constantly enhancing its influence on market development. In 2024, dsm-firmenich, leaders in nutrition, health and beauty, and Lallemand Health Solutions, experts in probiotics, revealed a revolutionary collaboration to introduce novel synergistic synbiotic offerings for early life nutrition. The innovative solutions merged human milk oligosaccharides (HMOs) from dsm-firmenich with probiotics from Lallemand Health Solutions to deliver possible synergistic advantages that promote infant health and growth. These solutions target fostering a microbiome similar to that of breast-fed infants and advancing the immune system, the gut microbiome, and ideal developmental pathways.

Human Microbiome Industry Segmentation:

The publisher provides an analysis of the key trends in each segment of the global human microbiome market, along with forecast at the global, regional, and country levels from 2026-2034. The market has been categorized based on product, application, and disease type.

Analysis by Product:

• Probiotics
• Prebiotics
• Diagnostic Tests
• Drugs
• Medical Food
• Others

Probiotics stand as the largest component in 2025, holding 43.2% of the market. Probiotics are providing major health advantages by maintaining the balance of healthy bacteria in the human gut. Live microorganisms are enhancing digestive wellness by promoting nutrient uptake, modulating bowel function, and lowering the risk of gastrointestinal illness like diarrhea, constipation, and irritable bowel syndrome. Through a balanced gut microbiome, probiotics are enhancing the body's own defense systems against disease-causing pathogens. Along with supportive digestive function, probiotics are boosting immune system function. They are activating antibody production and affecting immune cell function, and this is assisting the body in responding better to infection. Probiotics are also aiding metabolic health through aiding in weight management and enhancing insulin sensitivity, thus lowering risks associated with obesity and type 2 diabetes. Rising research is emphasizing their contribution to mental health, with gut microbiota affecting brain function via the gut-brain axis. This link is displaying promising implications for the reduction of stress, mood modulation, and cognitive function.

Analysis by Application:

• Therapeutics
• Diagnostics

Therapeutics lead the market with 82.1% of market share in 2025. They are yielding significant benefits by treating a broad array of medical ailments with tailored interventions. They are enhancing patient outcomes through treating chronic conditions, infectious diseases, and metabolic disorders using evidence-based modalities. Advanced therapeutics are moving beyond traditional medicines, as biologics, cell therapies, and microbiome therapies provide more targeted and personalized treatments. This transition is minimizing side effects while increasing treatment efficacy, as therapies become more addressed to the unique patient profile. Beyond disease treatment, therapeutics are stepping into preventive medicine as well. They are assisting in the early treatment of diseases like cardiovascular disease, diabetes, and cancer, thus reducing long-term medical expenses and enhancing the quality of life. Numerous therapeutics are also improving mental well-being by addressing neurological and psychiatric disorders so that they facilitate enhanced emotional and cognitive stability. Through ongoing improvements in biotechnology and genomics, therapeutics are providing safer, more efficacious, and highly individualized treatments.

Analysis by Disease Type:

• Obesity
• Diabetes
• Autoimmune Disorders
• Cancer
• Gastrointestinal Disorders
• Central Nervous System Disorders
• Others

Obesity leads the market with 26.9% of market share in 2025. Obesity, as a disease, is becoming a prominent area of focus in healthcare research because of its growing prevalence globally. Obesity is being realized as a multifactorial, chronic condition with etiologic factors related to genetics, behavior, environment, and metabolism. The ailment is linked to excess accumulation of fat that is compromising overall well-being and strongly increasing the risk of cardiovascular diseases, type 2 diabetes, hypertension, and some cancers. The increased prevalence of obesity is exacting a high economic and clinical cost on healthcare systems, leading to increased interest in preventive and curative approaches. Obesity has been studied as a focus area in the human microbiome market due to the influence of the microbiome on metabolism, energy balance, and fat storage. The work is revealing that disruptions in gut microbiota are adding to weight increase and metabolic disease. This awareness is propelling the formulation of microbiome-derived therapeutics, customized nutrition, and probiotics that can help better control and prevent obesity.

Regional Analysis:

• North America
• United States
• Canada
• Asia Pacific
• China
• Japan
• India
• South Korea
• Australia
• Indonesia
• Others
• Europe
• Germany
• France
• United Kingdom
• Italy
• Spain
• Russia
• Others
• Latin America
• Brazil
• Mexico
• Others
• Middle East and Africa

In 2025, North America accounted for the largest market share of 43.5%. The human microbiome sector in North America is experiencing growth as research institutions, biotechnology firms, and pharmaceutical companies are investing heavily in microbiome-focused innovations. The region is witnessing rising demand for microbiome-based therapeutics that are targeting gastrointestinal disorders, metabolic diseases, autoimmune conditions, and cancer. Companies are continuously developing advanced probiotics, prebiotics, and functional foods that are supporting digestive and immune health, while personalized nutrition solutions are gaining momentum as consumers are seeking individualized approaches to wellness. Technological advancements in next-generation sequencing and bioinformatics are enabling deeper analysis of microbial ecosystems, which is supporting clinical research and accelerating drug discovery. Funding from government agencies, venture capital firms, and private investors is increasing, allowing start-ups and established players to expand their pipelines and bring innovative products to market.

Key Regional Takeaways:

United States Human Microbiome Market Analysis

The United States holds 88.90% share in North America. The country is witnessing increased human microbiome adoption driven by the escalating burden of chronic lifestyle diseases. For instance, 6 out of 10 Americans have one chronic disease and four out of 10 have two or more chronic diseases that account for ninety percent of the USD 4.5 Trillion annual health care costs in the nation. The rising incidence of conditions such as cardiovascular disorders, metabolic syndrome, and inflammatory bowel diseases has spurred interest in personalized microbiome-based interventions. Healthcare systems are exploring microbiome-targeted therapies to manage and mitigate long-term complications associated with these chronic ailments. Pharmaceutical and biotech firms are investing in R&D focused on the gut-brain axis and gut-immune system. Additionally, patients are becoming more aware of microbiome diagnostics and probiotics as complementary strategies to traditional medicine. Growing public and private funding is reinforcing innovation in the microbiome segment.

Asia Pacific Human Microbiome Market Analysis

Asia-Pacific is experiencing accelerated human microbiome adoption influenced by the sharp increase in diabetes cases across the region. For instance, in 2025, diabetes had become a crucial health issue in India, with around 101 Million people currently diagnosed and 136 Million more estimated to be pre-diabetic. Rising sedentary lifestyles, dietary changes, and genetic predispositions have contributed to a growing diabetic population, prompting demand for innovative approaches to glucose regulation and metabolic health. Microbiome-based diagnostics and therapeutic solutions are gaining traction as they help identify gut flora imbalances linked to insulin resistance and type 2 diabetes. Research institutions and biotech companies are emphasizing microbiome modulation to prevent disease progression. As awareness about gut microbiota's role in metabolic health expands, preventive care programs and personalized nutrition plans incorporating microbiome data are gaining popularity.

Europe Human Microbiome Market Analysis

Europe is seeing a growing human microbiome adoption trend due to its increasing geriatric population. According to the WHO, the population aged 60 and older is rapidly growing in the WHO European Region. In 2021, there were 215 Million; by 2030, it is projected to be 247 Million, and by 2050, over 300 Million. As the elderly demographic expands, age-related health concerns such as weakened immunity, gastrointestinal issues, and neurodegenerative diseases are becoming more prevalent. Microbiome-focused healthcare solutions are being explored to improve longevity, manage inflammation, and enhance cognitive and digestive function. Researchers are developing microbiota-based therapies to support healthy aging, while nutraceutical companies are offering customized probiotics targeting age-specific concerns. Health institutions across the region are also integrating microbiome testing in geriatric care protocols.

Latin America Human Microbiome Market Analysis

Latin America is witnessing increased human microbiome interest as obesity cases continue to rise significantly. For instance, in LA about 64% of adults are overweight, from which 30.5% are obese, with numbers on the rise and affecting the entire population from early childhood. The prevalence of poor dietary habits and reduced physical activity is driving metabolic disorders across various age groups. Microbiome-based interventions are being studied for their ability to modulate gut flora, reduce inflammation, and assist in weight management.

Middle East and Africa Human Microbiome Market Analysis

Middle East and Africa are adopting human microbiome solutions at a growing pace due to the increasing cancer cases observed across the region. For instance, Saudi Arabia reported 27% of the GCC's total cancer cases, with an estimated 18,000 new diagnoses annually. With cancer treatments often impacting gut health and immunity, microbiome-targeted therapies are being incorporated into supportive care regimens. Researchers and healthcare providers are exploring how gut microbiota modulation can enhance treatment outcomes, reduce side effects, and improve recovery.

Competitive Landscape:

Market players in the human microbiome industry are actively engaging in research collaborations, product innovation, and strategic partnerships to strengthen their market presence. Companies are investing in advanced sequencing technologies and bioinformatics platforms to accelerate drug discovery and develop microbiome-based therapeutics targeting gastrointestinal, metabolic, and autoimmune disorders. Food and supplement manufacturers are launching probiotics, prebiotics, and functional foods that are catering to rising consumer demand for gut health and preventive care. Partnerships between pharmaceutical firms, biotech start-ups, and academic institutions are fostering innovation and clinical validation. Additionally, as per human microbiome market forecasts, market players are expected to secure funding from investors and government agencies, expanding clinical pipelines, and focusing on personalized nutrition and precision medicine to capture growing opportunities.

The report provides a comprehensive analysis of the competitive landscape in the human microbiome market with detailed profiles of all major companies, including:

• 4D pharma plc
• Atlas Biomed Group Limited
• BIOHM
• BiomX, Bione
• DayTwo Inc.
• ENTEROME
• Ferring B.V.
• Finch Therapeutics
• Second Genome Inc.
• SynBioBeta LLC
• Synthetic Biologics Inc.
• Vedanta Biosciences Inc.
• Viome Inc.

Key Questions Answered in This Report

• 1.How big is the human microbiome market?
• 2.What is the future outlook of human microbiome market?
• 3.What are the key factors driving the human microbiome market?
• 4.Which region accounts for the largest human microbiome market share?
• 5.Which are the leading companies in the global human microbiome market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Human Microbiome Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Product

• 6.1 Probiotics
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Prebiotics
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast
• 6.3 Diagnostic Tests
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast
• 6.4 Drugs
  • 6.4.1 Market Trends
  • 6.4.2 Market Forecast
• 6.5 Medical Food
  • 6.5.1 Market Trends
  • 6.5.2 Market Forecast
• 6.6 Others
  • 6.6.1 Market Trends
  • 6.6.2 Market Forecast

7 Market Breakup by Application

• 7.1 Therapeutics
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Diagnostics
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast

8 Market Breakup by Disease Type

• 8.1 Obesity
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Diabetes
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Autoimmune Disorders
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast
• 8.4 Cancer
  • 8.4.1 Market Trends
  • 8.4.2 Market Forecast
• 8.5 Gastrointestinal Disorders
  • 8.5.1 Market Trends
  • 8.5.2 Market Forecast
• 8.6 Central Nervous System Disorders
  • 8.6.1 Market Trends
  • 8.6.2 Market Forecast
• 8.7 Others
  • 8.7.1 Market Trends
  • 8.7.2 Market Forecast

9 Market Breakup by Region

• 9.1 North America
  • 9.1.1 United States
    • 9.1.1.1 Market Trends
    • 9.1.1.2 Market Forecast
  • 9.1.2 Canada
    • 9.1.2.1 Market Trends
    • 9.1.2.2 Market Forecast
• 9.2 Asia-Pacific
  • 9.2.1 China
    • 9.2.1.1 Market Trends
    • 9.2.1.2 Market Forecast
  • 9.2.2 Japan
    • 9.2.2.1 Market Trends
    • 9.2.2.2 Market Forecast
  • 9.2.3 India
    • 9.2.3.1 Market Trends
    • 9.2.3.2 Market Forecast
  • 9.2.4 South Korea
    • 9.2.4.1 Market Trends
    • 9.2.4.2 Market Forecast
  • 9.2.5 Australia
    • 9.2.5.1 Market Trends
    • 9.2.5.2 Market Forecast
  • 9.2.6 Indonesia
    • 9.2.6.1 Market Trends
    • 9.2.6.2 Market Forecast
  • 9.2.7 Others
    • 9.2.7.1 Market Trends
    • 9.2.7.2 Market Forecast
• 9.3 Europe
  • 9.3.1 Germany
    • 9.3.1.1 Market Trends
    • 9.3.1.2 Market Forecast
  • 9.3.2 France
    • 9.3.2.1 Market Trends
    • 9.3.2.2 Market Forecast
  • 9.3.3 United Kingdom
    • 9.3.3.1 Market Trends
    • 9.3.3.2 Market Forecast
  • 9.3.4 Italy
    • 9.3.4.1 Market Trends
    • 9.3.4.2 Market Forecast
  • 9.3.5 Spain
    • 9.3.5.1 Market Trends
    • 9.3.5.2 Market Forecast
  • 9.3.6 Russia
    • 9.3.6.1 Market Trends
    • 9.3.6.2 Market Forecast
  • 9.3.7 Others
    • 9.3.7.1 Market Trends
    • 9.3.7.2 Market Forecast
• 9.4 Latin America
  • 9.4.1 Brazil
    • 9.4.1.1 Market Trends
    • 9.4.1.2 Market Forecast
  • 9.4.2 Mexico
    • 9.4.2.1 Market Trends
    • 9.4.2.2 Market Forecast
  • 9.4.3 Others
    • 9.4.3.1 Market Trends
    • 9.4.3.2 Market Forecast
• 9.5 Middle East and Africa
  • 9.5.1 Market Trends
  • 9.5.2 Market Breakup by Country
  • 9.5.3 Market Forecast

10 SWOT Analysis

• 10.1 Overview
• 10.2 Strengths
• 10.3 Weaknesses
• 10.4 Opportunities
• 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

• 12.1 Overview
• 12.2 Bargaining Power of Buyers
• 12.3 Bargaining Power of Suppliers
• 12.4 Degree of Competition
• 12.5 Threat of New Entrants
• 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

• 14.1 Market Structure
• 14.2 Key Players
• 14.3 Profiles of Key Players
  • 14.3.1 4D pharma plc
    • 14.3.1.1 Company Overview
    • 14.3.1.2 Product Portfolio
    • 14.3.1.3 Financials
  • 14.3.2 Atlas Biomed Group Limited
    • 14.3.2.1 Company Overview
    • 14.3.2.2 Product Portfolio
  • 14.3.3 BIOHM
    • 14.3.3.1 Company Overview
    • 14.3.3.2 Product Portfolio
  • 14.3.4 BiomX
    • 14.3.4.1 Company Overview
    • 14.3.4.2 Product Portfolio
  • 14.3.5 Bione
    • 14.3.5.1 Company Overview
    • 14.3.5.2 Product Portfolio
  • 14.3.6 DayTwo Inc.
    • 14.3.6.1 Company Overview
    • 14.3.6.2 Product Portfolio
  • 14.3.7 ENTEROME
    • 14.3.7.1 Company Overview
    • 14.3.7.2 Product Portfolio
  • 14.3.8 Ferring B.V.
    • 14.3.8.1 Company Overview
    • 14.3.8.2 Product Portfolio
  • 14.3.9 Finch Therapeutics
    • 14.3.9.1 Company Overview
    • 14.3.9.2 Product Portfolio
    • 14.3.9.3 Financials
  • 14.3.10 Second Genome Inc.
    • 14.3.10.1 Company Overview
    • 14.3.10.2 Product Portfolio
  • 14.3.11 SynBioBeta LLC
    • 14.3.11.1 Company Overview
    • 14.3.11.2 Product Portfolio
  • 14.3.12 Synthetic Biologics Inc.
    • 14.3.12.1 Company Overview
    • 14.3.12.2 Product Portfolio
  • 14.3.13 Vedanta Biosciences Inc.
    • 14.3.13.1 Company Overview
    • 14.3.13.2 Product Portfolio
  • 14.3.14 Viome Inc.
    • 14.3.14.1 Company Overview
    • 14.3.14.2 Product Portfolio